|
Disease | Model | Role of Th17 | Reference |
|
Rheumatoid arthritis | Collagen-induced arthritis (CIA) | IL-23 (p19 subunit) KO mice have less Th17 cells and reduced disease severity | [35] |
Collagen-induced arthritis (CIA) | IL-17A KO mice have reduced disease incidence and severity | [36] |
IL-6R subunit gp130 (Y759F) mutation | Enforced IL-6 expression enhances disease progression in an IL-17A-dependent manner | [37] |
SKG-dominant active ZAP70 mutant | IL-17A KO mice are resistant to arthritis | [39] |
HTLV-I Tg mice | IL-17A KO mice are resistant to arthritis | [41] |
|
Inflammatory Bowel disease | Adoptive transfer of CD4+CD45RBhi cells to lymphopenic mice | IL-17A KO CD4+ T cells accelerated T-cell-mediated intestinal damage | [42] |
Adoptive transfer of CD4+CD45RBhi cells to lymphopenic mice | IL-17A, IL-17F, or IL-22 KO T-cells-induced colitis equally compared to WT | [43] |
Dextran sodium sulfate (DSS) | IL-17F KO or IL-17A KO or mice treated with an anti-IL-17A antibody showed severe weight loss and colonic epithelial damage | [44, 45] |
Dextran sodium sulfate (DSS) | IL-17A KO showed substantially reduced colitis based on both clinical score and mortality | [46] |
|
| Topical application of imiquimod (IMQ) | Dermatitis is blocked in IL-23R KO and IL-17R KO mice | [53] |
Psoriasis | IL-23 injection | IL-6-dependent accumulation of Th17 cells in psoriatic skin, dermatitis was greatly reduced in IL-22 KO or IL-17A KO mice | [55, 56] |
| K5.Stat3C transgenic mice |
Constitutively express activated Stat3 within keratinocytes promotes Th17 cells, and anti-IL-23 was shown to block epidermal hyperplasia; however, anti-IL-17 had only partial effect | [57] |
|
Type 1 diabetes | RIP-OVA mice (mice expressing OVA peptide in pancreatic beta islet cells ) | IL-17 producing CD8+ T cells (Tc17) cause diabetes in an IL-17A- and IL-17F-dependent manner when adoptively transferred to RIP-OVA mice | [59] |
Nonobese diabetes (NOD) | Anti-IL-17A antibodies inhibit diabetes during the effector phase of disease (at 10 weeks of age) but not during the initiation of disease (mice less than 5 weeks of age) | [60] |
|